Yaohai Bio

About Yaohai Bio

Yaohai Bio-Pharma, established in 2010, operates as a Contract Research, Testing, Development, and Manufacturing Organization (CRTDMO) with a specific focus on microbial expression systems. The firm provides comprehensive, end-to-end biopharmaceutical services for a global clientele. Its core business revolves around a business-to-business (B2B) model, offering customized development and manufacturing solutions to biotechnology and pharmaceutical companies, thereby supporting their drug development pipelines from initial research to commercial production.

The company's service portfolio is extensive, covering the entire drug life cycle. This includes engineering bacteria construction, strain bank establishment, process development and optimization, pilot scale-up, and compliant GMP production. Yaohai Bio-Pharma specializes in manufacturing a range of biological products, such as recombinant proteins, peptides, enzymes, antibody fragments, plasmid DNA, and mRNA. They also have capabilities in producing nanobodies and novel recombinant vaccines. Revenue is generated by providing these integrated CRO, CDO, CTO, and CMO services to partners in the pharmaceutical industry.

Operationally, Yaohai Bio-Pharma boasts a significant infrastructure, including a cGMP production platform with a fermentation scale exceeding 7,500 liters across a 20,000 square meter facility. The company is noted as the largest GMP-level plasmid supplier in China. Its facilities and quality management systems have successfully passed inspections by international regulatory bodies, including the FDA and NMPA. The company serves a diverse global market that includes North America, Europe, and various regions across Asia, Africa, and South America. Headquartered in China Medical City and with a presence in Beijing, the firm employs over 400 people.